Dominari Holdings Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Dominari Holdings Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $123.10M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $20.97M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.04M | Apr 15, 2025 |
| FY2020 | Dec 31, 2019 | $9.0K | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $28.0K | Feb 3, 2020 |
| FY2018 | Dec 31, 2017 | $1.24M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $877.0K | Mar 30, 2018 |
| FY2016 | Dec 31, 2015 | $33.0K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $10.0K | Mar 29, 2016 |
| FY2014 | Dec 31, 2013 | $27.0K | Mar 30, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($22.44M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($14.70M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($22.88M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($22.11M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($7.17M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($12.34M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($4.18M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $1.73M | Feb 3, 2020 |
| FY2018 | Dec 31, 2017 | ($3.31M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($6.48M) | Mar 30, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($55.73M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($8.70M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($21.80M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($14.35M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($9.44M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($6.55M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($5.69M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($6.87M) | Feb 3, 2020 |
| FY2018 | Dec 31, 2017 | ($3.82M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($8.55M) | Mar 30, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $3.0K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $830.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $559.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.02M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $10.0K | Mar 25, 2021 |
| FY2014 | Dec 31, 2013 | $10.0K | Mar 30, 2015 |
| FY2012 | Dec 31, 2012 | $727.1K | Mar 20, 2013 |
| FY2012 | Dec 31, 2011 | $1.65M | Mar 20, 2013 |
| FY2011 | Dec 31, 2010 | $4.85M | Mar 29, 2012 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $11.68M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $7.73M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $4.06M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $3.17M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $3.32M | Feb 3, 2020 |
| FY2018 | Dec 31, 2017 | $493.0K | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $253.0K | Mar 30, 2018 |
| FY2016 | Dec 31, 2015 | $534.0K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $1.70M | Mar 29, 2016 |
| FY2014 | Dec 31, 2013 | $1.01M | Mar 30, 2015 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.72M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($16.73M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($22.23M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($10.60M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($6.60M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($4.02M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($3.02M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($2.73M) | Feb 3, 2020 |
| FY2018 | Dec 31, 2017 | ($3.27M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $70.0K | Mar 30, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $427.0K | Apr 15, 2025 |
| FY2019 | Dec 31, 2018 | $36.0K | Feb 3, 2020 |
| FY2017 | Dec 31, 2016 | $4.0K | Mar 30, 2018 |
| FY2016 | Dec 31, 2015 | $2.0K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $4.0K | Mar 29, 2016 |
| FY2013 | Dec 31, 2012 | $2.0K | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $2.4K | Mar 20, 2013 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $112.91M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $47.13M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $57.56M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $76.24M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $102.66M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $30.50M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $11.28M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $13.25M | Feb 3, 2020 |
| FY2018 | Dec 31, 2017 | $8.97M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $11.28M | Mar 30, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $43.54M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $7.27M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $4.64M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $2.47M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.06M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $877.0K | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $750.0K | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $1.15M | Feb 3, 2020 |
| FY2018 | Dec 31, 2017 | $4.87M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $5.96M | Mar 30, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $39.85M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $52.92M | Apr 15, 2025 |
| FY2024 | Dec 31, 2022 | $73.77M | Apr 15, 2025 |
| FY2023 | Dec 31, 2021 | $101.60M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $29.62M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $10.53M | Mar 28, 2022 |
| FY2020 | Dec 31, 2018 | $12.10M | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | $4.11M | Feb 3, 2020 |
| FY2018 | Dec 31, 2016 | $5.32M | Mar 12, 2019 |
| FY2017 | Dec 31, 2015 | $8.75M | Mar 30, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2014 | $1.71M | Mar 29, 2016 |
| FY2014 | Dec 31, 2013 | $1.71M | Mar 30, 2015 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($268.13M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($223.47M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($208.76M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($185.88M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($163.77M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($156.60M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($144.27M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($140.08M) | Feb 3, 2020 |
| FY2019 | Jan 2, 2018 | $3.20M | Feb 3, 2020 |
| FY2018 | Dec 31, 2017 | ($145.06M) | Mar 12, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.01M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $4.08M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.83M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $33.17M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $65.56M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.72M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $91.0K | Mar 25, 2021 |
| FY2020 | Dec 31, 2018 | $17.0K | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | $197.0K | Feb 3, 2020 |
| FY2018 | Dec 31, 2016 | $134.0K | Mar 12, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | (4) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 31, 2023 |
| FY2019 | Dec 31, 2019 | (1) | Feb 3, 2020 |
| FY2019 | Dec 31, 2018 | 0 | Feb 3, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 12, 2019 |
| FY2016 | Dec 31, 2016 | 6 | Mar 31, 2017 |
| FY2016 | Dec 31, 2015 | (24) | Mar 31, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | (4) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 31, 2023 |
| FY2019 | Dec 31, 2019 | (1) | Feb 3, 2020 |
| FY2019 | Dec 31, 2018 | 0 | Feb 3, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 12, 2019 |
| FY2016 | Dec 31, 2016 | 6 | Mar 31, 2017 |
| FY2016 | Dec 31, 2015 | (24) | Mar 31, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 16.07M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 6.98M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 5.93M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 5.02M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 5.28M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 34.92M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | 4.83M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | 2.01M | Feb 3, 2020 |
| FY2018 | Dec 31, 2017 | 6.23M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | 4.94M | Mar 30, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.90M | Mar 31, 2026 |